Biogen (BIIB)
(Delayed Data from NSDQ)
$218.73 USD
+0.92 (0.42%)
Updated May 28, 2024 04:00 PM ET
After-Market: $218.00 -0.73 (-0.33%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Brokerage Reports
0 items in cart
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 101 - 120 ( 802 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Importance of Real World Evidence in Drug Approvals-Insights From AD/PD 2023 Gothenburg
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 3/17/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Win for Surrogate Biomarkers in CNS diseases-Broader Implications
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 32123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 3/10/23
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 31123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 3/3/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 3123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 22123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 2/10/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Full Potential of Leqembi Might Need Rapid Development of Blood-Based Biomarkers; Reit. Buy and $325 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
4Q22 First Take: Still On The Lookout For Strategic Updates
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 21123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 2/3/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Zuranolone Zipping Along As FDA Accepts Filing, Grants Priority Review
Provider: Wedbush Securities Inc.
Analyst: CHICO L